TOKYO – Peptidream Inc.'s stock, which had surged on Monday after inking a $1 billion-plus collaboration agreement, might have failed to keep the momentum going on Tuesday. But the news of a multitarget discovery and optimization collaboration agreement with U.S.-based Janssen Pharmaceuticals Inc. underscored the growth of the company, which now has 17 funded discovery collaboration deals. (See BioWorld Today, April 10, 2017.)